Relationship between XPA, XPB/ERCC3, XPF/ERCC4, and XPG/ERCC5 Polymorphisms and the Susceptibility to Head and Neck Carcinoma: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis

Imani, Mohammad Moslem; Basamtabar, Masoumeh; Akbari, Sattar; Sadeghi, Edris; Sadeghi, Masoud

doi:10.3390/medicina60030478

Cited by 4 publications

(1 citation statement)

References 54 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ERCC3 is the largest subunit of RNA polymerase II transcription factor H (TFIIH) [17], and the ERCC3 protein functions as a DNA deconjugating enzyme, also known as XPB. The ERCC3 gene is an essential component of NER, which is involved in the human DNA repair disorders of chromodermatosis pilaris [18], Cockayne's syndrome, and hairy sulfur dystrophy [19]. Genetic variants in ERCC3 may induce ovarian [14], breast [20], osteosarcoma [21], and pancreatic cancers [9].…”

Section: Introductionmentioning

confidence: 99%

ERCC3 serves as a prognostic biomarker for hepatocellular carcinoma and positively regulates cell proliferation and migration

Yang,

Du,

Qiu

et al. 2024

Preprint

View full text Add to dashboard Cite

Background ERCC3 is an important member of the nucleotide excision repair (NER) pathway, and its overexpression is involved in the development of a variety of cancers and is a potential factor for poor tumor prognosis. Currently, the expression and function of ERCC3 in hepatocellular carcinoma (HCC) remain unclear. Methods The aim of this study was to investigate the expression and clinical significance of ERCC3 in HCC tissues. The differential expression of ERCC3 across cancers and the characteristics of genetic variation were evaluated using the TCGA database. The TCGA, GEO and ICGC datasets were combined to examine the expression and prognostic value of ERCC3 in HCC. The independent prognostic value of ERCC3 expression levels in HCC was explored based on Cox regression analysis, Kaplan‒Meier survival analysis, receiver operating characteristic (ROC) curves and nomograms. The ssGSEA method was used to determine the pathway association coefficients to reveal the biological function of ERCC3 in HCC and the potential clinical efficacy of immunotherapy. An ERCC3-overexpressing lentivirus was used to infect HepG2 cells and establish a stable transient cell line, and RTCA, wound healing, and Transwell assays were applied to detect the effects of ERCC3 on the biological phenotypes of HCC cells. Flow cytometry was used to detect the distribution of the cell cycle and apoptosis. Transcriptome sequencing was used to explore the effect of ERCC3 gene overexpression on the expression of genes involved in signaling pathways in HCC. Results The results showed that ERCC3 appeared to be abnormally expressed in a variety of tumors, that ERCC3 mRNA and protein expression levels were significantly greater in HCC tissues than in normal tissues, and that high ERCC3 expression was significantly correlated with poor survival in HCC patients. Multivariate Cox regression analysis revealed that the ERCC3 expression level was an independent prognostic factor for overall survival (P = 0.014). The gene set associated with the high ERCC3 group was significantly involved in multiple immune pathways and tumor progression-related pathways, and ERCC3 expression was significantly associated with immune checkpoints in HCC. The overexpression of the ERCC3 gene promoted HCC cell proliferation and migration and affected cell cycle progression. Transcriptome sequencing analysis revealed that the overexpression of ERCC3 regulated HCC cell proliferation, participated in multiple proinflammatory pathways, induced the formation of an inflammatory microenvironment in tumors, and promoted HCC progression. Conclusions High expression of ERCC3 may be a poor prognostic factor for HCC patients and may play an immunomodulatory role in HCC, providing a theoretical basis for the development of targeted immunotherapy for hepatocellular carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

ERCC3 serves as a prognostic biomarker for hepatocellular carcinoma and positively regulates cell proliferation and migration

Yang,

Du,

Qiu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

A Meta-Analysis of Association Between Interleukin Polymorphisms (rs4073, rs1800925, rs1179251, rs1179246, rs2227485, rs17855750, and rs153109) and Colorectal Cancer Risk

Sadafi,

Amirifard,

Aleagha

et al. 2024

Biochem Genet

View full text Add to dashboard Cite

Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to head and neck carcinoma: a systematic review with five analyses

Sadafi,

Choubsaz,

Kazemeini

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Glutathione S-transferase theta 1 (GSTT1) enzyme plays a key role in the neutralization of electrophilic compounds such as carcinogens. Herein, we aimed to evaluate GSTT1 deletion polymorphism and susceptibility to head and neck carcinoma (HNC) according to 107 articles in a systematic review with five analyses. The databases of PubMed/Medline, Web of Science, Scopus, and Cochrane Library from the beginning of each database until June 21, 2023, with no restrictions to identify pertinent articles. The RevMan 5.3 software was used to calculate the effect sizes, which were displayed as the odds ratio (OR) along with a 95% confidence interval (CI). Both the publication bias and sensitivity analyses were performed using the CMA 3.0 software. A trial sequential analysis (TSA) was conducted. Of the 1966 records retrieved from four databases, 107 articles were included in the analysis. The combined analysis revealed that the pooled OR was 1.28 (95% CI: 1.14 to 1.44; p-value < 0.0001). The pooled OR was highest in mixed ethnicity. Nasopharyngeal cancer had the highest OR (1.84), followed by oral cancer (OR = 1.20), and laryngeal cancer (OR = 1.17). Studies with less than 200 samples had a higher OR compared to those with 200 or more samples. The studies with a quality score of 7 or more had a higher OR compared to those with a score of less than 7. When both age and sex are considered, while the OR of 1.42 is significant, the high heterogeneity suggests caution in interpreting these results. There is no evidence of publication bias. TSA reported that the study does not have sufficient statistical power. This comprehensive meta-analysis revealed a significant association between the GSTT1 null genotype and an increased risk of HNC, with variations based on factors such as ethnicity, cancer type, sample size, control source, and quality score.

show abstract

Relationship between XPA, XPB/ERCC3, XPF/ERCC4, and XPG/ERCC5 Polymorphisms and the Susceptibility to Head and Neck Carcinoma: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis

Cited by 4 publications

References 54 publications

ERCC3 serves as a prognostic biomarker for hepatocellular carcinoma and positively regulates cell proliferation and migration

ERCC3 serves as a prognostic biomarker for hepatocellular carcinoma and positively regulates cell proliferation and migration

A Meta-Analysis of Association Between Interleukin Polymorphisms (rs4073, rs1800925, rs1179251, rs1179246, rs2227485, rs17855750, and rs153109) and Colorectal Cancer Risk

Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to head and neck carcinoma: a systematic review with five analyses

Contact Info

Product

Resources

About